Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma (vol 98, pg 464, 2023)

被引：0
|
作者：
Desai, S. H.
Spinner, M. A.
David, K.
机构：
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2023年 / 98卷 / 11期
关键词：
D O I：
10.1002/ajh.27103
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1818 / 1818
页数：1
相关论文
共 23 条
  • [1] Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma
    Desai, Sanjal H.
    Spinner, Michael A.
    David, Kevin
    Bachanova, Veronika
    Goyal, Gaurav
    Kahl, Brad
    Dorritie, Kathleen
    Azzi, Jacques
    Kenkre, Vaishalee P.
    Arai, Sally
    Chang, Cheryl
    Fusco, Brendon
    Sumransub, Nuttavut
    Hatic, Haris
    Saba, Raya
    Ibrahim, Uroosa
    Harris, Elyse, I
    Shah, Harsh
    Murphy, Jacob
    Ansell, Stephen
    Jagadish, Deepa
    Orellana-noia, Victor
    Diefenbach, Catherine
    Iyenger, Siddharth
    Rappazzo, K. C.
    Mishra, Rahul
    Choi, Yun
    Nowakowski, Grzegorz S.
    Advani, Ranjana H.
    Micallef, Ivana N.
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (03) : 464 - 471
  • [2] Novel Salvage Regimens Lead to Better Response and Survival in Relapsed Refractory Classic Hodgkin Lymphoma after Autologous Stem Cell Transplant
    Desai, Sanjal H.
    Spinner, Michael A.
    David, Kevin A.
    Bachanova, Veronika
    Goyal, Gaurav
    Azzi, Jacques
    Dorritie, Kathleen
    Kenkre, Vaishalee P.
    Chang, Cheryl
    Arai, Sally
    Fusco, Brendon
    Sumransub, Nuttavut
    Hactic, Haris
    Ibrahim, Uroosa
    Harris, Elyse
    Maurer, Matthew J.
    Rappazzo, K. C.
    Orellana-Noia, Victor M.
    Diefenbach, Catherine S.
    Raya, Saba
    Nowakowski, Grzegorz S.
    Advani, Ranjana
    Micallef, Ivana N.
    BLOOD, 2021, 138
  • [3] Novel Salvage Regimens Lead to Better Response and Survival in Relapsed/Refractory Classic Hodgkin Lymphoma After Autologous Stem Cell Transplant
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 5 - 7
  • [4] ‘Relative’ chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma
    CI Chen
    D Roitman
    R Tsang
    AK Stewart
    A Keating
    M Crump
    Bone Marrow Transplantation, 2002, 30 : 885 - 891
  • [5] 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma
    Chen, CI
    Roitman, D
    Tsang, R
    Stewart, AK
    Keating, A
    Crump, M
    BONE MARROW TRANSPLANTATION, 2002, 30 (12) : 885 - 891
  • [6] SECOND LINE SALVAGE REGIMENS PRIOR TO HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANT ARE A VALID OPTION IN PROGRESSIVE HODGKIN'S LYMPHOMA PATIENTS REFRACTORY TO FIRST LINE SALVAGE REGIMENS
    Rauf, M. Shahzad
    Maghfoor, I.
    Elhassan, T. Ahmed M.
    Akhtar, S.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S173 - S174
  • [7] Five-Year Survival and Durability Results of the Phase 2 Trial Using the Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine)As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Classic Hodgkin Lymphoma
    Santoro, Armando
    Mazza, Rita
    Pulsoni, Alessandro
    Re, Alessandro
    Bonfichi, Maurizio
    Zilioli, Vittorio Ruggero
    Salvi, Flavia
    Anastasia, Antonella
    Luminari, Stefano
    Gotti, Manuel
    Peli, Annalisa
    Liberati, Anna Marina
    Di Renzo, Nicola
    Castagna, Luca
    Giordano, Laura
    Carlo-Stella, Carmelo
    BLOOD, 2018, 132
  • [8] 18FDG-PET-NEGATIVE COMPLETE REMISSION PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION PREDICTS FOR SUPERIOR EVENT FREE SURVIVAL OF PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA
    Peinert, S.
    Hoyt, R.
    Grigg, A.
    Prince, H. M.
    Seymour, J. F.
    Rigacci, L.
    Roberts, A.
    Szer, J.
    Ritchie, D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 34 - 34
  • [9] Complete Remission on 18F-FDG-PET Prior to Autologous Stem Cell Transplantation Predicts Superior Event Free Survival of Patients with Relapsed or Refractory Hodgkin Lymphoma
    Peinert, Stefan
    Hoyt, Rosemary
    Szer, Jeffrey
    Seymour, John F.
    Prince, H. Miles
    Roberts, Andrew W.
    Rigacci, Luigi
    Grigg, Andrew
    Ritchie, David S.
    BLOOD, 2008, 112 (11) : 763 - 764
  • [10] POST TRANSPLANT OUTCOMES IN A MULTICENTER PHASE II STUDY OF BRENTUXIMAB VEDOTIN AS FIRST LINE SALVAGE THERAPY IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION
    Herrera, A.
    Palmer, J.
    Martin, P.
    Armenian, S.
    Tsai, N. -C.
    Mott, M.
    Sahebi, F.
    Cai, J. -L.
    Siddiqi, T.
    Popplewell, L.
    Nademanee, A.
    Rosen, S.
    Kwak, L.
    Forman, S.
    Chen, R.
    HAEMATOLOGICA, 2016, 101 : 47 - 48
123